News - Biotechnology
AusBiotech calls for cutting-edge topics for 2020 conference

AusBiotech is calling for session proposals and speakers for AusBiotech 2020, to be held in Melbourne, 28 – 30 October.
Compelling stories or presentations on new, innovative research, projects or approaches to industry development, and inspirational, cutting-edge session topics are sought for showcasing to a global biotech industry.
AusBiotech is seeking speakers who are forward-thinking, diverse, engaging and who drive meaningful discussion about the business of biotech. Thought-provoking session ideas should explore current trends, critical and emerging topics, breakthroughs, and stories from a range of areas that encourage creative conversations both locally and abroad.
The annual AusBiotech conference brings together more than 1,000 leading innovative thinkers and inventors across the Australian and international biotech sector.
Applications for sessions will close at 5.00 pm, 28 February 2020. Submit your proposal now.
AusBiotech is committed to diversity and inclusion, and submissions for panels will only be considered if they meet a balanced gender representation threshold.
News - MedTech & Diagnostics
Hearts4heart takes aim at health insurers leaving patients to pay the price
Persistent advocacy by patient groups has prompted the Medical Services Advisory Committee (MSAC) to review the funding gaps for pulsed […]
MoreNews - MedTech & Diagnostics
Queensland first: Private hospitals deploy Abbott’s PFA in atrial fibrillation
More Australians living with atrial fibrillation (AF) are gaining access to one of the latest advances in heart-rhythm treatment, with […]
MoreNews - Pharmaceuticals
Five years of HTA reform talk, now comes the $47 billion question
Medicines Australia has put a $47 billion price tag on what it says Australia must invest to improve equitable access […]
MoreNews - Pharmaceuticals
New MFN deals raise the stakes for Australia’s delayed HTA reform
Four months after the US Trump administration concluded what was expected to be the final tranche of drug-pricing agreements with […]
More